Request Discount

Pneumococcal Vaccines Market (Product Type - Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine; Distribution Channel - Clinics, Hospitals, Non-governmental Organizations, and Government Authorities): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025

  • Published : June, 2019

  • Rep Id : HC0527

  • Category : Healthcare & Medical Devices

  • Status : Published

This report provides exclusive insights into the COVID-19 impact on the Pneumococcal Vaccines Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Pneumococcal Vaccines Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Pneumococcal Vaccines Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.

A recent report published by Infinium Global Research on pneumococcal vaccines market provides in-depth analysis of segments and sub-segments in the global as well as regional pneumococcal vaccines market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional pneumococcal vaccines market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global pneumococcal vaccines market. According to the report, the global pneumococcal vaccines market is projected to grow at a CAGR of 3.3% over the forecast period of 2019-2025.


Global Pneumococcal Vaccines Market


Market Insight

Pneumococcal diseases are the outcome of infections caused by streptococcus pneumoniae bacteria commonly known as pneumococcus. The vaccine helps in prevention of pneumococcal diseases caused by pneumococcus. There are two types of vaccines currently available pneumococcal conjugate vaccine PCV 10/PCV13 and pneumococcal polysaccharide vaccine PPSV23. PCV13 is suggested for children between 6 to 18 years of age and adults with medical conditions.  PPSV23 is administered to population above 65 years and adults, in certain cases it is given to the infants who are above two years of age.  The WHO has suggested pneumococcal conjugate vaccines in the routine immunization for children.

 

Rising prevalence of pneumococcal diseases such as pneumonia, sepsis, and meningitis is a major driving factor for the growth of pneumococcal vaccines market. The infection spread though pneumococcus is the main cause of morbidity and mortality globally. According to NCBI, it is estimated that approximately 335,000 (240,000–460,000) deaths in children aged greater than 5 years have occurred in 2015 globally. This increases the need for vaccination and drives the pneumococcal vaccines market.  Additionally, initiatives taken by the government and private organizations to provide vaccination and new target population leads to the growth of pneumococcal vaccines market. However, the high cost associated with the manufacturing of vaccines is restraining the growth of pneumococcal vaccines market. The new research techniques on vaccines and growing demand from developing regions are providing opportunities for the growth of pneumococcal vaccines market in the coming years.

 

Amongst the Geographies, North America is anticipated to hold maximum share in the pneumococcal vaccine market. Increased investment in the R&D sector and favorable government initiatives are the major factors responsible for the growth of the market in the North America region. Europe holds the second largest share in the pneumococcal drug market. Importance aspects of communicable diseases and threats related to it are heading the growth of the pneumococcal vaccine market. The Asia Pacific is estimated to witness the highest growth rate during the forecast period. The growth of this region is attributed due to growing awareness regarding pneumococcal vaccine and increasing incidences of pneumonia.

 

Segment Covered

The report on global pneumococcal vaccines market covers segments such as product type and distribution channel. On the basis of product type, the sub-markets include pneumococcal conjugate vaccine, and pneumococcal polysaccharide vaccine. On the basis of the distribution channel, the sub-markets include clinics, hospitals, non-governmental organizations, and government authorities.

 

Companies Profiled:

The report provides profiles of the companies in the market such as Bayer AG, GlaxoSmithKline plc, Pfizer Inc., Nuron Biotech Inc., CSL Ltd., Biomed Pvt. Ltd., Serum Institute of India Pvt. Ltd., Sanofi Pasteur Inc., JN-International Medical Corporation, and Merck & Co., Inc.

 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of pneumococcal vaccines market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount